Related Experiment Video
Updated: Jan 23, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma
Chengrui Yan1,2, Jiaru Wang2, Yuyan Yang2
1Department of Neurosurgery, Peking University International Hospital, Beijing, China.
Abstract:
Despite aggressive multimodality treatment, the prognosis of glioma, especially malignant glioma, remains very poor. After decades of effort, anti-angiogenic therapy has become an important method of cancer treatment in addition to surgery, radiotherapy and chemotherapy. Although the performance of anti-angiogenic therapy in colorectal cancer is good, its performance in malignant glioma remains unsatisfactory. Several phase III clinical trials showed no overall survival benefits. To solve this problem, the division of patients into groups based on their molecular biomarkers is an important step. This paper provides current insights into anti-angiogenic drugs undergoing clinical trials and discusses the potential of molecular biomarkers to guide glioma diagnosis.
Insights
Anti-angiogenic therapy shows limited success in malignant glioma treatment. Molecular biomarkers are crucial for stratifying patients and improving treatment efficacy in glioma diagnosis and therapy.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Malignant glioma has a poor prognosis despite aggressive treatments.
- Anti-angiogenic therapy is a key cancer treatment but underperforms in malignant glioma.
- Clinical trials show no overall survival benefits for anti-angiogenic therapy in glioma.
Purpose of the Study:
- To review current anti-angiogenic drugs in clinical trials for glioma.
- To discuss the role of molecular biomarkers in guiding glioma diagnosis and treatment.
- To explore strategies for improving anti-angiogenic therapy outcomes in glioma.
Main Methods:
- Literature review of anti-angiogenic drugs in clinical trials.
- Analysis of molecular biomarker applications in glioma.
- Discussion of challenges and future directions in glioma therapy.
Main Results:
- Anti-angiogenic therapy has shown limited efficacy in malignant glioma.
- Molecular biomarkers are essential for patient stratification.
- Several anti-angiogenic drugs are under investigation in clinical trials.
Conclusions:
- Personalized medicine approaches using molecular biomarkers are vital for advancing glioma treatment.
- Further research is needed to optimize anti-angiogenic strategies for glioma patients.
- Biomarker-guided therapy holds promise for improving outcomes in malignant glioma.
More Related Videos
07:44Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
Published on: March 25, 2022
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Gene Therapy
Molecular Models
Molecular Orbital Theory II
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
Molecular Orbital Theory I